Tag:

AstraZeneca

Latest Headlines

Latest Headlines

AstraZeneca opens Indian IT center as 13-year outsourcing experiment nears end

AstraZeneca is following the well-trodden path of offshoring part of its IT to India. But unlike some of its peers--and in a reversal of its own strategy--the Big Pharma is adding in-house capacity and lessening its reliance on IT service providers.

AstraZeneca sends James Van Der Beek 'camping' to promote FluMist Quadrivalent

To get the word out on AstraZeneca's needle-free FluMist Quadrivalent vaccine, the company has brought on James Van Der Beek--of "Dawson's Creek" fame--to participate in its "Insist on the Mist" campaign.

Can AstraZeneca turn its Movantik constipation pill into a blockbuster?

AstraZeneca's brand-new Movantik has an edge on rivals in the opioid-induced constipation (OIC) market, which is expected to near $2 billion by 2017. It's the first mu-opioid approved for OIC, and the first mu-opioid pill, period.

AZ faces market-making task to capitalize on Movantik's edge in OIC

Congratulate AstraZeneca and Nektar Therapeutics. Their oral therapy for opioid-related constipation, Movantek, beat all rival pills to market. And if analysts are correct, that market lead will pay off big time.

AstraZeneca sends James Van Der Beek 'camping' to promote flu vaccination

AstraZeneca's FluMist Quadrivalent is the only needle-free, four-strain flu vaccine--and the company wants to make sure people know it. It's brought on James Van Der Beek--of "Dawson's Creek" fame--to participate in its "Insist on the Mist" campaign.

AstraZeneca and Nektar win FDA OK for blockbuster-hopeful constipation drug

The FDA approved a new opioid-induced constipation treatment from partners AstraZeneca and Nektar Therapeutics, shaking off some safety concerns and green-lighting a drug the two hope can bring in billions.

Eli Lilly takes the lead on AstraZeneca's Alzheimer's drug in $500M deal

Longtime Alzheimer's player Eli Lilly has agreed to pay $50 million in a near-term milestone and take charge of the development work in a collaboration package worth a total of up to $500 million.

Would Ian Read keep his AZ deal promises? U.K. panel eyes new rules to enforce them

Remember all those industrial and investment promises Pfizer made when it was trying to snag AstraZeneca earlier this year? The body that polices U.K. dealmaking is eyeing new rules that would give it more power to enforce such promises, should Pfizer--or another company--come calling in the future.

Recruitment specialist Trialbee snags a deal with AstraZeneca

Trialbee, a Swedish patient-recruitment outfit, has added AstraZeneca to its client roster, bringing its direct-to-patient technology to the U.K. drugmaker.

AstraZeneca taps Trialbee for online patient recruitment

Trialbee has added another large pharma to its list of clients, with AstraZeneca following Novo Nordisk in signing up to work with the online trial recruitment specialist. The AstraZeneca deal spans multiple regions, therapeutic areas and phases of clinical trials.